NCT03822117: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations

NCT03822117
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have an FGFR 1/2 or 3 gene mutation or translocation
Exclusions: Patients with untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed- see trial for details
https://ClinicalTrials.gov/show/NCT03822117

Comments are closed.

Up ↑